[go: up one dir, main page]

ZA200802453B - Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists - Google Patents

Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists

Info

Publication number
ZA200802453B
ZA200802453B ZA200802453A ZA200802453A ZA200802453B ZA 200802453 B ZA200802453 B ZA 200802453B ZA 200802453 A ZA200802453 A ZA 200802453A ZA 200802453 A ZA200802453 A ZA 200802453A ZA 200802453 B ZA200802453 B ZA 200802453B
Authority
ZA
South Africa
Prior art keywords
imidazole derivatives
adrenoreceptor agonists
functionally selective
selective alpha2c
alpha2c adrenoreceptor
Prior art date
Application number
ZA200802453A
Other languages
English (en)
Inventor
Kevin D Mccormick
Robert G Aslanian
Fevrier Salem
Huang Chia-Yu
Liu Rong-Qiang
Christopher W Boyce
Shih Neng-Yang
Mangiarcina Peitro
Liang Bo
Lu Huagang
Original Assignee
Schering Corp
Pharmacopeia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37401474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200802453(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp, Pharmacopeia Inc filed Critical Schering Corp
Publication of ZA200802453B publication Critical patent/ZA200802453B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
ZA200802453A 2005-08-25 2008-03-17 Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists ZA200802453B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71139805P 2005-08-25 2005-08-25

Publications (1)

Publication Number Publication Date
ZA200802453B true ZA200802453B (en) 2008-12-31

Family

ID=37401474

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200802453A ZA200802453B (en) 2005-08-25 2008-03-17 Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists

Country Status (19)

Country Link
US (1) US7803828B2 (xx)
EP (1) EP1945626B1 (xx)
JP (1) JP2009506047A (xx)
KR (1) KR20080039982A (xx)
CN (1) CN101296920A (xx)
AR (1) AR056043A1 (xx)
AT (1) ATE517883T1 (xx)
AU (1) AU2006283104A1 (xx)
BR (1) BRPI0615307A2 (xx)
CA (1) CA2620171A1 (xx)
EC (1) ECSP088222A (xx)
IL (1) IL189679A0 (xx)
NO (1) NO20081426L (xx)
PE (1) PE20070336A1 (xx)
RU (1) RU2008110908A (xx)
SG (1) SG165314A1 (xx)
TW (1) TWI316515B (xx)
WO (1) WO2007024944A1 (xx)
ZA (1) ZA200802453B (xx)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
JP5099814B2 (ja) * 2006-02-02 2012-12-19 田辺三菱製薬株式会社 含窒素複素二環式化合物
EP2076497B1 (en) 2006-10-19 2012-02-22 F. Hoffmann-La Roche AG Aminomethyl-4-imidazoles
EP2086959B1 (en) 2006-11-02 2011-11-16 F. Hoffmann-La Roche AG Substituted 2-imidazoles as modulators of the trace amine associated receptors
JP2010510184A (ja) 2006-11-16 2010-04-02 エフ．ホフマン−ラ ロシュ アーゲー 置換４−イミダゾール類
MX2009005920A (es) 2006-12-13 2009-06-16 Hoffmann La Roche Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina.
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
NZ578260A (en) 2007-02-02 2012-02-24 Hoffmann La Roche Novel 2-aminooxazolines as taar1 ligands for cns disorders
BRPI0807961A2 (pt) * 2007-02-13 2017-05-16 Pharmacopeia Llc agonista de alfa2c adrenorreceptor funcionalmente seletivos.
MX2009008777A (es) * 2007-02-13 2009-08-25 Schering Corp Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
CA2678072A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
BRPI0807813A2 (pt) 2007-02-15 2014-08-05 Hoffmann La Roche 2-amino-oxazolinas como ligantes de taar1
EP2173720A2 (en) 2007-07-02 2010-04-14 F. Hoffmann-Roche AG 2-imidazolines having a good affinity to the trace amine associated receptors (taars)
BRPI0812833A2 (pt) 2007-07-03 2014-12-09 Hoffmann La Roche 4-imidazolinas e seu uso como antidepressivos
WO2009016048A1 (en) 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
BRPI0814758A2 (pt) 2007-08-03 2015-03-03 Hoffmann La Roche Piridinacarboxamida e derivados de benzamida como ligantes taar1
EA201000808A1 (ru) * 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US20110190247A1 (en) * 2008-08-04 2011-08-04 Schering Corporation Cyclopropylchromene derivatives as modulators of the alpha-2c receptor
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
WO2010033495A2 (en) * 2008-09-16 2010-03-25 Schering Corporation Functionally selective azanitrile alpha2c adrenoreceptor agonists
AR073628A1 (es) 2008-10-07 2010-11-17 Schering Corp Analogos de biaril espiroaminooxazolina y espiroaminodiazolina moduladores de receptores adrenergicos alfa2c, composiciones farmaceuticas que los comprenden y uso de los mismos en rinitis alergica,trastornos cardiacos y otras enfermedades
GB0909671D0 (en) 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
GB0909672D0 (en) 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
SG186989A1 (en) 2010-07-14 2013-02-28 Novartis Ag Ip receptor agonist heterocyclic compounds
CA2816753A1 (en) * 2010-11-08 2012-05-18 Lycera Corporation N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases
EP2646429B1 (en) * 2010-12-01 2014-10-15 Janssen Pharmaceutica NV 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of ccr2
LT2734186T (lt) 2011-07-22 2018-12-10 Glaxosmithkline Llc Kompozicija
JP6073923B2 (ja) 2012-01-13 2017-02-01 ノバルティス アーゲー 肺動脈高血圧症（ｐａｈ）および関連障害の治療のためのｉｐ受容体アゴニストとしての縮合ピロール
MX367341B (es) 2012-05-08 2019-08-14 Merck Sharp & Dohme Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
US9394315B2 (en) 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
MX359671B (es) 2012-08-24 2018-10-05 Glaxosmithkline Llc Star Compuestos de pirazolopiridina.
JP6228223B2 (ja) 2012-11-20 2017-11-08 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 新規化合物
RU2643371C2 (ru) 2012-11-20 2018-02-01 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Новые соединения
BR112015011439A2 (pt) 2012-11-20 2017-07-11 Glaxosmithkline Llc composto, composição farmacêutica, composição de vacina, e, uso de um composto
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
MX2017007607A (es) 2014-12-11 2018-05-28 Harvard College Inhibidores de necrosis celular y metodos relacionados.
WO2016130818A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
AU2016257997A1 (en) 2015-05-05 2017-11-09 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
AU2016276947A1 (en) 2015-06-11 2017-12-14 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
BR112018002399A2 (pt) 2015-08-06 2018-09-25 Chimerix, Inc. nucleosídeos de pirrolopirimidina e análogos dos mesmos, úteis como agentes antivirais
AR105911A1 (es) 2015-09-03 2017-11-22 Forma Therapeutics Inc Inhibidores de hdac8 bicíclicos fusionados [6,6]
MX2018005004A (es) 2015-10-27 2018-09-12 Merck Sharp & Dohme Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
EP3368516B1 (en) 2015-10-27 2020-07-15 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EP3368535B1 (en) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
HRP20201405T1 (hr) 2016-03-17 2020-11-27 F. Hoffmann - La Roche Ag Derivat 5-etil-4-metil-pirazol-3-karboksamida, koji djeluje kao agonist taar-a
EP3684771B1 (en) 2017-09-21 2024-11-27 Chimerix, Inc. Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7h-pyrrolo(2,3-d)pyrimidine-5-carboxamide and uses thereof
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
JP2022536755A (ja) * 2019-06-14 2022-08-18 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
PH12022550361A1 (en) 2019-08-14 2023-02-27 Incyte Corp Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
CN117529475A (zh) 2021-01-08 2024-02-06 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的含脲或类似物的杂双环化合物及其化合物
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
GB202112240D0 (en) * 2021-08-26 2021-10-13 Univ Court Univ St Andrews Inhibitor compounds
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
PL447976A1 (pl) * 2024-03-11 2025-09-15 Celon Pharma Spółka Akcyjna Pochodna imidazolo-indolowa wiążąca się z receptorem serotoninowym 5-HT7, kompozycja farmaceutyczna zawierająca tę pochodną, zastosowania pochodnej i kompozycji oraz produkt pośredni do wytwarzania pochodnej imidazolo-indolowej

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK151884C (da) * 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
FR2735776B1 (fr) * 1995-06-22 1997-07-18 Synthelabo Derives de 2,3-dihydro-1h-indole, leur preparation et leur application en therapeutique
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
WO1997048697A1 (en) * 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5866579A (en) * 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US20030087962A1 (en) * 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
CA2402405C (en) * 2000-07-14 2008-02-12 Allergan Sales, Inc. Compositions containing alpha-2-adrenergic agonist components
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
ES2222832B1 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
EP1791832A1 (en) * 2004-09-24 2007-06-06 Allergan, Inc. 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
CN101247853B (zh) * 2005-04-13 2014-11-12 轴突公司 具有nos抑制活性的取代的吲哚化合物

Also Published As

Publication number Publication date
KR20080039982A (ko) 2008-05-07
EP1945626B1 (en) 2011-07-27
BRPI0615307A2 (pt) 2009-08-04
TWI316515B (en) 2009-11-01
SG165314A1 (en) 2010-10-28
AU2006283104A1 (en) 2007-03-01
ECSP088222A (es) 2008-03-26
ATE517883T1 (de) 2011-08-15
US20070099872A1 (en) 2007-05-03
NO20081426L (no) 2008-05-23
TW200808768A (en) 2008-02-16
RU2008110908A (ru) 2009-09-27
AR056043A1 (es) 2007-09-12
JP2009506047A (ja) 2009-02-12
EP1945626A1 (en) 2008-07-23
PE20070336A1 (es) 2007-04-16
WO2007024944A1 (en) 2007-03-01
CA2620171A1 (en) 2007-03-01
IL189679A0 (en) 2008-06-05
US7803828B2 (en) 2010-09-28
CN101296920A (zh) 2008-10-29

Similar Documents

Publication Publication Date Title
ZA200802453B (en) Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
IL189678A0 (en) Alpha2c adrenoreceptor agonists
IL214183A (en) Pharma-informatics system and method, preparation for use with it and method for preparation of the preparation
ZA200806148B (en) 2-adamantylurea derivatives as selective 11ß-HSD1 inhibitors
IL200395A0 (en) Functionally selective alpha2c adrenoreceptor agonists
IL200424A0 (en) Functionally selective alpha 2c adrenoreceptor agonists
BRPI0718688A2 (pt) Composições de baixa irritação e métodos para preparar as mesmas.
ZA200708491B (en) Pyridine-3-carboxamide derivatives as CB1 inverse agonists
PL2094263T3 (pl) Pochodne 2-adamantylo-butyroamidowe jako selektywne inhibitory 11beta-HSD1
ZA200901268B (en) Substituted imidazolone derivatives, preparation and uses
ZA200810640B (en) 1,5 -Diphenylpyrazoles II as HSP90 Inhibitors
IL198462A0 (en) Diazepane-acetamide derivatives as selective 11??-hsd1 inhibitors
EP2282735A4 (en) COMPOUNDS, COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
ZA201008657B (en) 4,5-dihydro-oxazol-2-yl derivatives
IL188486A0 (en) Benzimidazole derivatives as 5-ht6,5-ht24
GB0819432D0 (en) Compound, composition and use
IL184559A0 (en) Imidazole derivatives
IL179314A0 (en) Aminopyridine derivatives as selective dopamine d3 agonists
IL186119A0 (en) 7-fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents
HK1119684A (en) Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
WO2009105504A3 (en) Functionally selective alpha2c adrenoreceptor agonists
HK1137453A (en) Functionally selective alpha2c adrenoreceptor agonists
HK1135105A (en) Functionally selective alpha2c adrenoreceptor agonists
IL213328A0 (en) Regeneration of 2,2'-cyclopropylidene-bis (oxazolines)
ZA200807362B (en) Bezothiazol derivatives as beta2 adrenoreceptor agonists